Published in Blut on July 20, 1977
Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 1.58
Prostacyclin deficiency in thrombotic thrombocytopenic purpura. Lancet (1979) 1.27
Experimental vitamin K deficiency and spontaneous metastases. Br J Cancer (1977) 1.26
Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol (2010) 1.16
The effect of heparin on the initial phase of metastasis formation. Eur J Cancer (1972) 1.15
Experimental hypercalcaemia and whole blood clotting. J Clin Pathol (1973) 1.10
Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL). Br J Cancer (1977) 1.01
Ifosfamide--current aspects and perspectives. Cancer Treat Rev (1983) 1.01
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol (1989) 0.99
The role of blood platelets in experimental metastases. Br J Cancer (1973) 0.95
Microangiopathic haemolytic anaemia and experimental tumour-cell emboli. Br J Haematol (1974) 0.94
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog Exp Tumor Res (1992) 0.93
D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother Pharmacol (1995) 0.93
The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z Krebsforsch Klin Onkol Cancer Res Clin Oncol (1976) 0.92
Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols. J Cancer Res Clin Oncol (1984) 0.92
Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors. J Biol Chem (1998) 0.91
Microangiopathic haemolytic anaemia associated with hypercalcaemia in an experimental rat tumour. Br J Haematol (1973) 0.90
Anticoagulants in the treatment of cancer. Eur J Cancer (1976) 0.90
Acute hypercalcemia due to Walker carcinosarcoma 256 in the rat. Horm Metab Res (1970) 0.89
Aspirin and tumour metastasis. Lancet (1972) 0.89
Platelet shape change abnormalities in diabetic retinopathy. Diabetologia (1980) 0.88
Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization. Rofo (2010) 0.87
Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat (1992) 0.87
Factor X-activating activity from Lewis lung carcinoma. Br J Cancer (1980) 0.87
A novel casein kinase 2 alpha-subunit regulates membrane protein traffic in the human hepatoma cell line HuH-7. J Biol Chem (2000) 0.87
High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: preliminary data of a phase-II study. Onkologie (1988) 0.85
Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene (1996) 0.84
[Intravascular coagulation in solid Walker carcinosarcoma 256]. Schweiz Med Wochenschr (1971) 0.84
[Hypercalcemic activity of Walker carcinosarcoma 256 in the rat]. Schweiz Med Wochenschr (1971) 0.84
Mechanism of lung tumour colony reduction caused by coumarin anticoagulation. Eur J Cancer (1979) 0.84
High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study. Onkologie (1988) 0.84
Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Eur J Cancer (1995) 0.83
[Determination of the carcinoembryonic antigen (CEA) for predicting the success of therapy in metastatic breast cancer]. Dtsch Med Wochenschr (1983) 0.82
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treat Rev (1990) 0.82
Tumor-associated antigens in effusions of malignant and benign origin. Clin Investig (1993) 0.81
The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity. Arzneimittelforschung (1989) 0.80
Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines. Eur J Cancer (1994) 0.80
Thrombin-induced disseminated intravascular coagulation. III:Modification by dextran infusion. Br J Anaesth (1975) 0.79
Synthesis of procoagulant antihaemophilic factor in vitro. Lancet (1979) 0.79
Intra-arterial perfusion therapy with 5-fluorouracil in patients with metastatic colorectal carcinoma and intractable pelvic pain. Recent Results Cancer Res (1983) 0.79
Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems. J Cancer Res Clin Oncol (1981) 0.79
Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. J Cancer Res Clin Oncol (1992) 0.79
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial. Onkologie (1988) 0.78
Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives. Cancer Treat Rev (1985) 0.78
Etoposide--chemistry, preclinical and clinical pharmacology. Cancer Treat Rev (1982) 0.78
Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol (1984) 0.78
Current development of podophyllotoxins. Cancer Chemother Pharmacol (1982) 0.78
Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro. Eur J Cancer (1993) 0.78
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. Clin Nephrol (2011) 0.78
A new platelet aggregating material (PAM) in an experimentally induced rat fibrosarcoma. Thromb Haemost (1984) 0.77
Studies of human serum amyloid P-component (SAP) in relation to coagulation. Clin Chim Acta (1980) 0.77
The key role of hydroxylation for the cytostatic activity and selectivity of cyclophosphamide. Invest New Drugs (1984) 0.77
[The cytotoxic effect of plasmin on yoshida sarcoma cells]. Z Krebsforsch (1969) 0.77
Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies. Biochim Biophys Acta (1990) 0.77
Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models. Cancer Immunol Immunother (1989) 0.77
Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg----His): fibrinogens Bergamo II, Essen and Perugia. Thromb Haemost (1986) 0.77
Highly sensitive northern hybridization of rare mRNA using a positively charged nylon membrane. Biotechniques (1994) 0.77
[Selective internal radiotherapy (SIRT) for hepatocellular carcinoma]. Rofo (2010) 0.77
The antitumor activity of the platinum complex D-17872 is associated with tumor cell differentiation. Cancer Chemother Pharmacol (1993) 0.77
Phase II evaluation of carboplatin in advanced esophageal carcinoma. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society. Onkologie (1990) 0.77
D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol (1990) 0.77
[Fibrinogen elevation in malignant tumors--an unspecific symptom]. Verh Dtsch Ges Inn Med (1969) 0.77
Basis and new developments in the field of oxazaphosphorines. Cancer Invest (1988) 0.77
Selection and characterization of mammalian cell lines with stable over-expression of human pituitary receptors for gonadoliberin. Eur J Biochem (1995) 0.77
Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone. Eur J Cancer (1996) 0.77
Induction of tumor cell differentiation by alkylphosphocholines: a new approach for in vitro screening. Prog Exp Tumor Res (1992) 0.76
Antiinvasive activity of hexadecylphosphocholine in vitro. Anticancer Res (1991) 0.76
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer. J Clin Oncol (1984) 0.76
Liver transplantation for hepatocellular carcinoma after yttrium therapy: a case report. Transplant Proc (2008) 0.76
Mechanisms of C. Parvum-induced coagulopathy in mice. Br J Cancer (1980) 0.75
Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother Pharmacol (1993) 0.75
[Immunologic typing of a circulation anticoagulant factor]. Med Welt (1975) 0.75
Proceedings: Cardiorespiratory changes associated with disseminated intravascular coagulation in the dog. Br J Anaesth (1973) 0.75
Anticancer drug development--problems and perspectives. Eur J Surg Oncol (1986) 0.75
Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis. Klin Wochenschr (1990) 0.75
Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry. Biomed Mass Spectrom (1985) 0.75
Glycoprotein-adsorption from cancer sera--influence on a mixed lymphocyte culture. J Clin Lab Immunol (1985) 0.75
In vitro adsorption of colon cancer sera over staphylococcus protein A: lymphocyte stimulation by leakage of adsorbance. Klin Wochenschr (1987) 0.75
Cancer and vitamin K. Lancet (1977) 0.75
Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication. Arzneimittelforschung (1989) 0.75
Induction of disseminated intravascular coagulation by endotoxin and saline loading in rats II. Fibrin deposition and removal. Thromb Res (1975) 0.75
Coagulant and fibrinolytic activities of a metastasising and non-metastasising tumour line. Indian J Cancer (1990) 0.75
Induction of disseminated intravascular coagulation by endotoxin and saline loading in rats. I. The influence on fibrinogen turnover and plasma parameters. Thromb Res (1975) 0.75
Selective cytostatic activity of hexadecylphosphocholine against tumor-cells invitro leads to the establishment of an invivo screening system for phospholipid analogs. Int J Oncol (1993) 0.75
[Separation and pharmaco-toxicological studies of the enantiomers of Ifosfamide]. Arzneimittelforschung (1986) 0.75
Anticancer drugs: estrophilic cisplatin derivatives. Cancer Treat Rev (1987) 0.75
Bone marrow purging with mafosfamide--a critical survey. Blut (1989) 0.75
Thrombin-induced disseminated intravascular coagulation in the dog. I: Demonstration of microthrombi in lung. Br J Anaesth (1975) 0.75
Podophyllotoxin analogues: synthesis and computer modelling investigation of structure-activity relationships. Anticancer Drug Des (1987) 0.75
Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression. J Cancer Res Clin Oncol (1989) 0.75
Platelet aggregation inhibiting and anticoagulant effects of oligoamines, XVI: Cytostatic and cytotoxic side effects of oligoamines. Arch Pharm (Weinheim) (1991) 0.75
Cause and prevention of mafosfamide-induced venous pain. Invest New Drugs (1986) 0.75
Protection from ifosfamide-induced alopecia by topical thiols in young rats. Cancer Chemother Pharmacol (1990) 0.75
[Studies on the cytolytic action of plasmin on Yoshida ascites sarcoma]. Arch Geschwulstforsch (1969) 0.75
Thrombin-induced disseminated intravascular coagulation in the dog. II. Cardiorespiratory changes during spontaneous and controlled ventilation. Br J Anaesth (1975) 0.75
Pulmonary vasoconstriction produced by protamine and protamine-heparin complex in the isolated cat lung perfused with blood or dextran. Cardiovasc Res (1975) 0.75
Bone marrow transplantation in acute leukemia [proceedings]. Pathol Biol (Paris) (1978) 0.75
[Studies of 131 I fibrinogen storage by the Yoshida sarcoma of rats]. Fortschr Geb Rontgenstr Nuklearmed (1973) 0.75
Phase II study of pirarubicin in metastatic breast cancer. Onkologie (1990) 0.75
Increased plasma fibrinogen and the release of a fibrinogen enhancing factor in tumour-bearing rats. Experientia (1970) 0.75